Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & Bristol Myers Squibb

16 shared events · Importance 5 · Last updated Aug 11, 2026

Importance
5
Shared Events
16
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
77
Business
United States: The US stands to gain from increased investment and manufacturing, aligning with the Trump administration's priorities. The deal would likely require US regulatory approval.
Bristol Myers Squibb: Bristol Myers Squibb is the target of the potential merger, which would provide it with a significant premium and access to AstraZeneca's pipeline. Its shares have risen 43% in the past year, and the deal could further boost its valuation.
Aug 02, 2026 · 60 articles
77
Business
United States: The United States is the focus of BMS's $40 billion investment plan, which includes this United States — Houston campus. The investment supports domestic manufacturing and innovation, aligning with broader national goals.
Bristol Myers Squibb: Bristol Myers Squibb is the primary investor, committing $2.3 billion to build a new manufacturing campus in United States — Houston. This investment is part of its $40 billion U.S. expansion plan and is expected to enhance its manufacturing capabilities and support future drug production.
Aug 10, 2026 · 20 articles
69
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Bristol Myers Squibb: Bristol Myers Squibb is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
68
Regulatory
United States: The US is drafting the investment rules through its Treasury Department, balancing national security concerns against pharmaceutical industry interests.
Bristol Myers Squibb: Bristol Myers Squibb signed a partnership with Jiangsu Hengrui worth up to $15.2 billion this year, a deal type the draft rules would likely preserve.
Sep 18, 2026 · 6 articles
49
Business
United States: Engaged in conflict with Iran, impacting oil prices and markets. Also intervened in yen markets.
Bristol Myers Squibb: Reportedly in merger talks with AstraZeneca, which could create a $400 billion drugmaker.
Jul 14, 2026 · 280 articles
42
Tech
United States: The studies discussed involve patients and practices within the United States>>> and address a significant health concern for American women.
Bristol Myers Squibb: Bristol Myers Squibb>>>'s immunotherapies Opdivo and Yervoy are mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Jun 02, 2026 · 45 articles
35
Business
United States: The United States is home to Bristol Myers and health authorities involved in the review.
Bristol Myers Squibb: Bristol Myers voluntarily paused Zola-cel studies as a precaution, reflecting broader industry caution in CAR-T autoimmune therapies.
Sep 01, 2026 · 7 articles
28
International
United States: The US is entering a new AI defence partnership with the UK while rejecting global AI controls, reinforcing its competitive advantage for American AI companies.
Bristol Myers Squibb: Christopher Boerner attended Burnham's business event; no direct impact.
Sep 22, 2026 · 22 articles
20
Business
United States: The United States is a major market where Optellum has partnerships and customer deployments, and where its LCP AI solution is FDA-cleared and Medicare-reimbursed.
Bristol Myers Squibb: Bristol Myers Squibb is a partner of Optellum in the US, supporting the commercial momentum of Optellum's AI solutions in lung cancer care.
Jun 04, 2026 · 6 articles
19
Business
United States: Key market where FDA approvals and Nasdaq-listed ADRs for the share consideration shape the deal's milestone structure and investor access.
Bristol Myers Squibb: Cited as a recent acquirer of radiopharmaceutical assets, part of the broader M&A trend in the industry.
Sep 21, 2026 · 6 articles
17
Regulatory
United States: The United States, through the FDA, approved the drug, making it available to American patients and potentially influencing global regulatory decisions.
Bristol Myers Squibb: Bristol Myers Squibb, another KRAS inhibitor developer, is similarly affected by the competitive landscape.
Aug 26, 2026 · 92 articles
14
Business
United States: The United States is the primary market for Lantheus' products and the regulatory jurisdiction for the deal, with potential antitrust review.
Bristol Myers Squibb: Bristol Myers Squibb is mentioned as a prior acquirer in the sector, highlighting the trend of radiopharmaceutical consolidation.
Aug 03, 2026 · 7 articles
12
Business
United States: The United States is mentioned as the regulator that rejected AstraZeneca's breast cancer drug camizestrant, part of the series of setbacks. This regulatory action affects AstraZeneca's US market prospects.
Bristol Myers Squibb: Bristol Myers Squibb was mentioned in the context of brief merger speculation involving AstraZeneca, which triggered investor backlash but is not directly part of this event.
Aug 17, 2026 · 20 articles
0
Regulatory
Dec 19, 2025 · 7 articles
0
Regulatory
Bristol Myers Squibb: Bristol Myers Squibb is one of the major drugmakers that has reached pricing agreements with the Donald Trump administration to avoid the new tariffs.
Apr 02, 2026 · 23 articles
0
Business
Bristol Myers Squibb: Bristol Myers Squibb is a drug sponsor engaged with Cellares' Cell Shuttle platform and has a $380 million global manufacturing agreement with Cellares, reserving commercial-scale capacity.
Jun 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States and Bristol Myers Squibb interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.